Navigation Links
Green tea’s health claims questioned: FD

A new finding and revelation comes in the form of health claims that green tea is no longer a boon to the heart. The petition proposed as a model qualified health// claim says "Daily consumption of at least 5 fluid ounces (150 mL) of green tea as a source of catechins may reduce a number of risk factors associated with cardiovascular disease. FDA has determined that the evidence is supportive, but not conclusive, for this claim. (Green tea provides 125 mg catechins per serving when brewed from tea and 125 mg catechins as a pre-prepared beverage)."

This petition was posted on the FDA site by FDA on July 28, 2005 as a qualified health claim petition for a 60-day comment period.

According to rules of governance a health claim characterizes the relationship between a substance and a disease or health-related condition (21 CFR 101.14(a)(1)). The substance must be associated with a disease or health-related condition for which the general U.S. population, or an identified U.S. population subgroup is at risk (21 CFR 101.14(b)(1)).

The agency then separates individual reports of human studies from other types of data and information. FDA focuses its review on reports of human intervention and observational studies.

In addition to individual reports of human studies, the agency also considers other types of data and information in its review, such as meta-analyses, review articles and animal and in vitro studies.

FDA uses animal and in vitro studies as background information regarding mechanisms of action that might be involved in any relationship between the substance and the disease. FDA evaluates the individual reports of human studies to determine whether any scientific conclusions can be drawn from each study. The absence of critical factors such as a control group or a statistical analysis means that scientific conclusions cannot be drawn from the study (Spilker et al., 1991, Federal Judicial Center, 2000).

Because health claims involve reducing the risk of a disease in people who do not already have the disease that is the subject of the claim, FDA considers evidence from studies in individuals diagnosed with the disease that is the subject of the health claim only if it is scientifically appropriate to extrapolate to individuals who do not have the disease.

Next, FDA rates the remaining human intervention and observational studies for methodological quality. This quality rating is based on several criteria related to study design (e.g., use of a placebo control versus a non-placebo controlled group), data collection (e.g., type of dietary assessment method), the quality of the statistical analysis, the type of outcome measured (e.g., disease incidence versus validated surrogate endpoint), and study population characteristics other than relevance to the U.S. population (e.g., selection bias and whether important information about the study subjects--e.g., age, smoker vs. non-smoker--was gathered and reported).

Finally, FDA evaluates the results of the remaining studies.

Although the model claim proposed in the petition refers only to green tea consumed as an article for drink, the discussion in the petition makes clear that the proposed claim is based on a body of evidence encompassing studies of green tea in both a beverage and an extract form.

It is not necessary for FDA to make a determination about the safety of green tea or green tea extract in this letter because the agency is denying the proposed claims for lack of credible evidence.

FDA has identified the following disease endpoints to use in identifying CVD risk reduction for purposes of a health claim evaluation: the incidence of coronary events (MI, ischemia), cardiovascular death, coronary artery disease, atherosclerosis, and coronary heart disease (CHD). High blood pressure, blood (serum or plasma) total cholesterol, and blood LD L-cholesterol levels are considered surrogate endpoints for all CVDs.[14] These disease and surrogate endpoints were used to evaluate the potential effects of green tea or green tea extract consumption on CVD risk.

Based on FDA's consideration of the scientific evidence and other information submitted with FDA concludes that there is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with CVD.


'"/>




Related medicine news :

1. Green tea beneficial in preventing osteoarthritis
2. Eating Greens fights cancer
3. Green Onions Blamed in Outbreak
4. Green Tea Might Help Patients With Prostate Cancer
5. Yet Another Use For Green Tea Extract
6. Exposure To Greenery And Graffiti May Affect Obesity
7. Green Beans for Cancer Prevention and Treatment.
8. Can Green Tea Prevent Alzheimers?
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Polyphenols in Green Tea Cause Liver Damage At High Doses
11. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed surgical ... of Saint Luke’s Health System . Dr. Upadhyaya has served in the role ... joins Stanley P. Fisher, M.D., who has served as medical co-director of ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... in Oakland, California effectively destroyed the construction site and threatened numerous homes and ... July 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
(Date:7/24/2017)... ... July 24, 2017 , ... The ... Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 standards. This ... and integrity in testing and calibration will be changed. , As an ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... Tuesday received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created ... the 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
Breaking Medicine Technology: